Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients

The Interaction among Insulin Resistance, Liver Fibrosis and Early Virological Response in Egyptian Patients with Chronic Hepatitis C

(2016) Dina H Ziada et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Apolipoprotein A-I mimetics and high-density lipoprotein function

(2013) Scott M. Gordon et al.   Current Opinion in Endocrinology Diabetes and Obesity

Anti-inflammatory and anti-atherogenic properties of adiponectin

(2012) Koji Ohashi et al.   BIOCHIMIE

Association of HCV with diabetes mellitus: an Egyptian case-control study

(2011) Eman I Elhawary et al.   Virology Journal

Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity

(2010) Alireza Esteghamati et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

The importance of steatosis in chronic hepatitis C infection and its management: A review

(2010) Timothy J. S. Cross et al.   HEPATOLOGY RESEARCH

Adipokines in liver diseases

(2009) Fabio Marra et al.   HEPATOLOGY

Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data

(2009) Lawrence Serfaty et al.   LIVER INTERNATIONAL

Visfatin, low-grade inflammation and body mass index (BMI)

(2008) Anastasia Samara et al.   CLINICAL ENDOCRINOLOGY

Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity

(2008) T. Luk et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Unknown

(2008) Katja Rabe et al.   MOLECULAR MEDICINE

Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage

(2007) Ranganath Muniyappa et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM